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For over a decade now, clinical and experimental researchers
have hunted for gene polymorphisms as a major cause of
hypertension, coronary artery disease (CAD) or heart fail-
ure, such as angiotensin-converting enzyme (ACE) poly-
morphisms, which were accused to be a major contributor of
cardiovascular diseases (1,2). Sequence variants of the com-
ponents of the renin-angiotensin-aldosterone system were
suggested to have significant influences on cardiovascular
homeostasis (2,3). Both gene targeting and studies using
transgenic mice suggested a critical role of the ACE gene in
blood pressure regulation. Moreover, since an up-regulation
of myocardial ACE gene expression has been observed
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in patients with heart failure, the ACE gene was one of the
favorites within the known gene polymorphisms and a top
candidate for cardiovascular researchers. Over 100 of base-
pair (bp) switches, insertions (I) or deletions (D) were
identified within the ACE-gene but only a few, namely the
ACE I/D, D/D, or I/I polymorphisms seemed to have a
significant impact on either CAD, hypertension or resteno-
sis following coronary stenting (CS). The ACE I/D poly-
morphism of a 287-bp Alu element within the intron 16 of
the ACE gene has attracted significant attention and has
been extensively investigated in a spectrum of cardiovascular
phenotypes because of its positive correlation with serum
ACE activity (4). In addition, several studies showed a
positive association between the ACE D/D genotype and
an increased risk of myocardial infarction (2). Yet the
association for hypertension, left ventricular hypertrophy,
cardiomyopathy, CAD and restenosis after percutaneous
transluminal coronary angioplasty remains controversial (4–
6). Even meta-analysis of several studies, statistical mimic-
ries and studies in very selected patients populations pro-
vided a rather confusing puzzle of results which ultimately
leaves it to the individual researcher, clinician, and journal
reviewer whether or not to believe the presented results
(2,3). Nevertheless, why should a single base pair polymor-
phism within the ACE gene result in such a complex
pathophysiological problem like restenosis following CS?
In this regard, neointimal hyperplasia, but not lumen
narrowing by arterial remodeling, controls the restenotic
process after CS. It remains to be determined, however,
whether chronic inflammatory processes induced by the
stent’s metal struts or components of the renin-angiotensin
system, namely ACE and angiotensin II are major contrib-
utors to the development of neointimal hyperplasia. Never-
theless, it is well accepted that polymorphisms within the
ACE gene may modulate the process of in-stent restenosis.
In addition, ACE polymorphisms may also affect the
response to ACE inhibitors although there is no consensus
as to which allele confers a more pronounced effect (7,8).
The ACE DD genotype of the ACE gene is associated with
higher circulating angiotensin II levels (4,9), but the patho-
physiological implication of enhanced angiotensin II levels
with regard to in-stent restenosis remained unclear. More-
over, because plasma ACE activity is under genetic control
of a functional mutation located within the ACE locus in
almost complete linkage disequilibrium with the ACE ID
polymorphism, the ACE ID genotypes were proposed to
predict in-stent restenosis (10).
In this issue of the Journal, the study by Koch et al. (11)
reported that carrier of the ACE DD polymorphism fol-
lowing CS are not at higher risk of restenosis or recurrent
myocardial infarction when treated with ACE inhibitors.
This study investigates the largest cohort of patients (2,222
ID genotype patients with symptomatic CAD, 622 ACE
DD carrier) and conclusively shows that the ACE polymor-
phism is of minor clinical importance following CS in
patients treated with ACE inhibitors. A variety of angio-
graphic parameters were investigated including minimal
lumen diameter, diameter stenosis or late lumen loss all of
which were associated with ACE genotype. This association
may appear puzzling with regard to a parameter such as
in-stent restenosis or lumen gain with stenting that may also
depend on skills and experience of the interventional cardi-
ologists. However, the convincing results of the present
study imply that pharmacological ACE inhibition can
overcome genetic determination by ACE polymorphisms.
However, this analysis has several limitations. First, the
duration of treatment with an ACE inhibitor prior to CS,
the tissue specificity of the ACE inhibitor used or the
daily dose varied. Yet, the beneficial effect was observed
in 95% of the study population receiving either enalapril
or captopril. Moreover, only 5% of the patients received
ramipril, an ACE inhibitor with a particularly high tissue
ACE affinity. These observations may be consistent with
the notion that ACE inhibition, independent of its tissue
ACE affinity elicits beneficial effects following CS and
may overcome the deleterious effects of specific ACE
polymorphisms.
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Moreover, this trial was not randomized and was per-
formed in a retrospective manner (11). Clearly, randomized
placebo-controlled trials without an ACE inhibitor are
needed to answer this question. However, these studies
will be difficult to design for ethical reasons since ACE
inhibition by ramipril in patients with CAD showed a
dramatic reduction of cardiovascular events in the
HOPE trial (Heart Outcome and Prevention Evaluation)
(12).
Finally, whether or not chronic angiotensin II type 1
(AT1)-receptor blockade will be equally effective as ACE
inhibition in the prevention of in-stent restenosis in patients
with various ACE polymorphisms is of particular clinical
interest and needs further evaluation. It is speculated that
ACE inhibition may be more effective in ACE DD carriers
as compared to AT1-receptor blockade, based on observa-
tions that both, AT1-receptor blockade and ACE DD
polymorphism are associated with higher serum levels an-
giotensin II. Therefore, it is postulated that AT1-receptor
blockade in ACE DD carriers would increase angiotensin II
levels in addition to already elevated angiotensin II serum
levels. This latter would synergistically enhance detrimental
cardiovascular effects of angiotensin II such as smooth
muscle cell hyperplasia for in-stent restenosis.
Moreover, the ACE ID polymorphism is associated with
higher ACE activity and should therefore be more effec-
tively treated with ACE inhibitors with high tissue ACE
affinity (e.g., quinapril or ramipril).
In summary, the study by Koch et al. (11) should have
clinical implications, since it solves some of our problems
with the ACE polymorphisms in the daily practice. With
regard to in-stent restenosis, we do not have to select our
treatment for patients with a specific genotype. The study by
Koch et al. (11) provides a very practicable clinical solution:
treat all patients with an adequate dose of an ACE inhibitor
and this will overcome the negative impact of ACE poly-
morphisms on in-stent restenosis following CS.
Reprint requests and correspondence: Dr. Bernhard Schieffer,
Abteilung Kardiologie und Angiologie, Medizinische Hochschule
Hannover, Carl Neuberg Strasse 1, 30625 Hannover, Germany.
E-mail: Schieffer.Bernhard@MH-Hannover.de.
REFERENCES
1. Cambien F, Poirier O, Lecerf L, et al. Deletion polymorphism in the
gene for angiotensin converting enzyme is a potent risk factor for
myocardial infarction. Nature 1992;359:641–4.
2. Agerholm-Larsen B, Nordestgaard BG, Tybjaerg-Hansen A. ACE
gene polymorphism in cardiovascular disease: meta analysis of small
and large studies. Arterioscler Thromb Vasc Biol 2000;20:484–92.
3. Schieffer B, Drexler H. ACE gene polymorphism and coronary artery
disease: a question of persuasion or statistical confusion? Arterioscler
Thromb Vasc Biol 2000;20:281–2.
4. Rigart B, Hubert C, Alhenc-Gelas F, et al. An insertion/deletion
polymorphism in the angiotensin I-converting enzyme gene account-
ing for half the variance of serum enzyme levels. J Clin Invest
1990;86:1343–6.
5. Danser AH, Schalekamp MA, Bax WA, et al. Angiotensin-converting
enzyme in the human heart: effect of the deletion/insertion polymor-
phism. Circulation 1995;92:1387–8.
6. Koch W, Kastrati A, Mehilli J, et al. Insertion/deletion polymorphism
of the angiotensin I-converting enzyme gene is not associated with
restenosis after coronary stent placement. Circulation 2000;102:197–
202.
7. Jorgensen E, Kelbaek H, Helqvist S, et al. Predictors of coronary
in-stent restenosis: importance of angiotensin-converting enzyme gene
polymorphism and treatment with angiotensin-converting enzyme
inhibitors. J Am Coll Cardiol 2001;38:1434–9.
8. Meurice T, Bauters C, Hermant X, et al. Effect of ACE inhibitors on
angiographic restenosis after coronary stenting (PARIS): a random-
ised, double-blind, placebo-controlled trial. Lancet 2001;357:1321–4.
9. Ribichini F, Steffenino G, Dellavalle A, et al. Plasma activity and
insertion/deletion polymorphism of angiotensin I-converting enzyme:
a major risk factor and a marker of risk for coronary stent restenosis.
Circulation 1998;97:147–54.
10. Amant C, Bauters C, Bodart JC, et al. D allele of the angiotensin
I-converting enzyme is a major risk factor for restenosis after coronary
stenting. Circulation 1997;96:56–60.
11. Koch W, Mehilli J, von Beckerath N, Bo¨ttiger C, Scho¨mig A, Kastrati
A. Angiotensin I–converting enzyme (ACE) inhibitors and restenosis
after coronary artery stenting in patients with the DD genotype of the
ACE gene. J Am Coll Cardiol 2003;41:1957–61.
12. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-
enzyme inhibitor, ramipril, on cardiovascular events in high-risk
patients. The Heart Outcomes Prevention Evaluation Study Investi-
gators. N Engl J Med 2000;342:145–53.
1963JACC Vol. 41, No. 11, 2003 Schieffer and Drexler
June 4, 2003:1962–3 Editorial Comment
